COACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer

Prior treatment

• Any prior prostate cancer treatment;
• Had any of the following within 6 months before randomization: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, heart failure with New York Heart Association Class Functional III or IV;
• Inability to swallow oral medications;

Other illness

• Unresectable prostate cancer;
• Histology of small cell carcinoma prostate cancer or adenocarcinoma with neuroendocrine features;
• Any active infection requiring IV antibiotics;
• Uncontrolled severe hypertension as indicated by a resting systolic BP ≥ 180 mmHg or diastolic BP ≥ 110 mmHg despite medical management;
• A gastrointestinal (GI) disorder or procedure which is expected to interfere significantly with absorption of darolutamide;

Lab values

• Receipt of medications (e.g. finasteride, dutasteride) or agents that are likely to alter serum PSA levels within \<= 42 days or 5 half-lives prior to registration, whichever is shorter.

Age

• Known additional malignancy that has a life-expectancy \< 2 years;

• Men ≥18 years of age;
• Histologically confirmed unfavorable intermediate or high/very high risk non metastatic (by conventional imaging) prostate adenocarcinoma intended for surgery without neuroendocrine differentiation or small cell features;
• Unfavorable intermediate-risk:
  • ISUP grade 3, and/or \> 50% positive biopsy cores and/or at least two intermediate-risk factors. Intermediate-risk factors:
  • Clinical tumor stage T2b or T2c (MRI based);
  • ISUP grade 2 or 3;
  • Prostate-specific antigen (PSA) level of 10-20 ng/mL.
• High-risk or very high-risk:
  • ≥cT3a (MRI based) or ISUP 4-5 or PSA\>20 ng/mL;
  • cN1.
• ECOG 0-1;
• Baseline testosterone \> 230 ng/dL;
• No prior prostate cancer treatment;
• Sexually active male subjects must agree to use condoms as an effective barrier method and refrain from sperm donation, and/or their female partners of reproductive potential to use a method of effective birth control, during the treatment with darolutamide and for 1 week after the end of treatment with darolutamide to prevent pregnancy;
• Written informed consent.